PURPOSE: To evaluate whether the pretreatment determination of serum chromogranin A (CgA) can provide information beyond that obtained with serum prostate specific antigen (PSA) and Gleason score at biopsy as a predictive factor of clinical understaging (T2-pT3) of prostate adenocarcinoma. MATERIALS: In this prospective study, we analyzed 83 consecutive patients with clinical T2N0M0 prostate adenocarcinoma submitted to radical prostatectomy (RRP). On the same day of RRP, before surgery, a blood sample for the determination of serum total PSA and CgA levels (RIA) was obtained. RESULTS: After RRP, 27 of the 83 cases (32.5%) showed extracapsular disease extension (pT3) at the final pathological examination and were considered clinically understaged. A significant association between serum CgA and pathological stage (r = 0.3830; P = 0.0004) was found. At the multivariate analysis, serum CgA and PSA, but not biopsy Gleason score, were found to be significant pretreatment independent predictors of pT3 at RRP (P = 0.00004 and P = 0.0018, respectively). The relative risk of clinical understaging significantly varied according to serum CgA levels. Using a CgA cut-off value of 60 ng/ml, PPV and NPV for clinical understaging were 0.5161 and 0.7885, respectively (P = 0.0072). CONCLUSIONS: Serum CgA could be incorporated into risk assessment models of newly diagnosed prostate cancer. Copyright 2003 Wiley-Liss, Inc.
PURPOSE: To evaluate whether the pretreatment determination of serum chromogranin A (CgA) can provide information beyond that obtained with serum prostate specific antigen (PSA) and Gleason score at biopsy as a predictive factor of clinical understaging (T2-pT3) of prostate adenocarcinoma. MATERIALS: In this prospective study, we analyzed 83 consecutive patients with clinical T2N0M0 prostate adenocarcinoma submitted to radical prostatectomy (RRP). On the same day of RRP, before surgery, a blood sample for the determination of serum total PSA and CgA levels (RIA) was obtained. RESULTS: After RRP, 27 of the 83 cases (32.5%) showed extracapsular disease extension (pT3) at the final pathological examination and were considered clinically understaged. A significant association between serum CgA and pathological stage (r = 0.3830; P = 0.0004) was found. At the multivariate analysis, serum CgA and PSA, but not biopsy Gleason score, were found to be significant pretreatment independent predictors of pT3 at RRP (P = 0.00004 and P = 0.0018, respectively). The relative risk of clinical understaging significantly varied according to serum CgA levels. Using a CgA cut-off value of 60 ng/ml, PPV and NPV for clinical understaging were 0.5161 and 0.7885, respectively (P = 0.0072). CONCLUSIONS: Serum CgA could be incorporated into risk assessment models of newly diagnosed prostate cancer. Copyright 2003 Wiley-Liss, Inc.
Authors: Christian Niedworok; Stephan Tschirdewahn; Henning Reis; Nils Lehmann; Miklós Szücs; Péter Nyirády; Imre Romics; Herbert Rübben; Tibor Szarvas Journal: Pathol Oncol Res Date: 2016-12-23 Impact factor: 3.201
Authors: Stefano Salciccia; Anna Laura Capriotti; Aldo Laganà; Stefano Fais; Mariantonia Logozzi; Ettore De Berardinis; Gian Maria Busetto; Giovanni Battista Di Pierro; Gian Piero Ricciuti; Francesco Del Giudice; Alessandro Sciarra; Peter R Carroll; Matthew R Cooperberg; Beatrice Sciarra; Martina Maggi Journal: Int J Mol Sci Date: 2021-04-22 Impact factor: 5.923
Authors: Stefano Salciccia; Alessandro Sciarra; Martina Moriconi; Martina Maggi; Pietro Viscuso; Davide Rosati; Marco Frisenda; Giovanni Battista Di Pierro; Vittorio Canale; Giulio Bevilacqua; Gianluca Nesi; Francesco Del Giudice; Alessandro Gentilucci; Susanna Cattarino; Gianna Mariotti Journal: J Clin Med Date: 2021-12-27 Impact factor: 4.241
Authors: Stefano Salciccia; Davide Rosati; Pietro Viscuso; Vittorio Canale; Emiliano Scarrone; Marco Frisenda; Roberta Catuzzi; Martina Moriconi; Vincenzo Asero; Stefano Signore; Mauro De Dominicis; Paolo Emiliozzi; Antonio Carbone; Antonio Luigi Pastore; Andrea Fuschi; Giovanni Battista Di Pierro; Alessandro Gentilucci; Susanna Cattarino; Gianna Mariotti; Gian Maria Busetto; Matteo Ferro; Ettore De Berardinis; Gian Piero Ricciuti; Valeria Panebianco; Fabio Massimo Magliocca; Francesco Del Giudice; Martina Maggi; Alessandro Sciarra Journal: Cent European J Urol Date: 2021-11-29
Authors: Simone Flammia; Marco Frisenda; Martina Maggi; Fabio Massimo Magliocca; Antonio Ciardi; Valeria Panebianco; Ettore De Berardinis; Stefano Salciccia; Giovanni Battista Di Pierro; Alessandro Gentilucci; Francesco Del Giudice; Gian Maria Busetto; Michele Gallucci; Alessandro Sciarra Journal: Medicine (Baltimore) Date: 2020-09-18 Impact factor: 1.817
Authors: Alessandro Sciarra; Marco Frisenda; Martina Maggi; Fabio Massimo Magliocca; Antonio Ciardi; Valeria Panebianco; Ettore De Berardinis; Stefano Salciccia; Giovanni Battista Di Pierro; Alessandro Gentilucci; Francesco Del Giudice; Gian Maria Busetto; Antonio Tufano Journal: Cent European J Urol Date: 2021-05-07